Get the Stockscreener App
8.625
0.52%
-0.045
Rallybio Corp stock is traded at $8.625, with a volume of 57,173.
It is down -0.52% in the last 24 hours and up +48.20% over the past month.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
See More
Previous Close:
$8.67
Open:
$8.74
24h Volume:
57,173
Relative Volume:
0.47
Market Cap:
$45.62M
Revenue:
$858.00K
Net Income/Loss:
$-8.98M
P/E Ratio:
-41.89
EPS:
-0.2059
Net Cash Flow:
$-29.81M
1W Performance:
-7.85%
1M Performance:
+48.20%
6M Performance:
+90.78%
1Y Performance:
+63.45%
1-Day Range:
$8.48
$9.00
1-Week Range:
$8.48
$9.50
52-Week Range:
$1.7608
$11.49
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
8.625 | 45.86M | 858.00K | -8.98M | -29.81M | -0.2059 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio to acquire Candid Therapeutics - MSN
Rallybio to acquire Candid Therapeutics in $505M merger deal - MSN
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
Halper Sadeh LLC is Investigating Whether RLYB, TALK, UNF are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Tiny biotech Rallybio stock surges as $500 million-backed merger fuels investor optimism - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization - TipRanks
Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB - GlobeNewswire Inc.
Rallybio Corporation 2025 10-K: Clinical-Stage Rare Disease Biotech, Pipeline, Partnerships, and Regulatory Overview - Minichart
RLYB Surges on Revenue and Merger Hype Why the Stock Still Dropped - Bitget
Stock Recap: What hedge funds are buying Rallybio CorporationPortfolio Value Summary & Weekly High Conviction Ideas - baoquankhu1.vn
Rallybio (NASDAQ: RLYB) to become Candid after merger, $505.5M financing - Stock Titan
Rallybio 2025 10-K: $0.858M Revenue, $(8.98)M Net Loss - TradingView
Rallybio (NASDAQ: RLYB) plans Candid merger, $505.5M financing and CVR structure - Stock Titan
Rallybio: Net loss improved to $9.0 million in 2025 amid a pending merger, asset sale, and cost reductions - TradingView
Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Candid Merging Into Public Market - San Diego Business Journal
RLYB Q4'25 Earnings: EPS estimate is (1.24) USD - TradingView
Retail Surge: Will Rallybio Corporation benefit from current market trendsNew Guidance & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Energy Moves: Can Rallybio Corporation generate free cash flowJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves - TipRanks
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? - PR Newswire
Geopolitics Watch: Whats the profit margin of Rallybio CorporationWeekly Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? (2026-03-06) - Seeking Alpha
Brokerages Set Rallybio Corporation (NASDAQ:RLYB) Price Target at $40.00 - Defense World
Rallybio (RLYB) Expected to Announce Earnings on Thursday - MarketBeat
$105M for Starface pimple patches, humanoid robot maker eyes €1B and Rallybio's reverse merger - Axios
Candid Therapeutics to Merge with Rallybio in Reverse Merger - themiddlemarket.com
Rallybio Investor Alert: Merger Investigation Launched - National Today
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation – RLYB - Weekly Voice
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - The AI Journal
Candid lists via Rallybio reverse merger, adds $505m financing - The Pharma Letter
Candid Therapeutics: $505 Million Financing And Merger With Rallybio To Advance Autoimmune T-Cell Engager Pipeline - Pulse 2.0
TPG group shows 7.2% Rallybio (RLYB) stake and supports Candid merger - Stock Titan
RLYB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rallybio merger deal includes $50M breakup fee, $200M financing floor - Hartford Business Journal
Latham & Watkins Advises on US$505 Million Financing in Connection With Rallybio-Candid Therapeutics Merger - Legal Desire Media and Insights
Rallybio, Candid Therapeutics announce merger agreement - TipRanks
Firm Advises Candid Therapeutics on Patent Matters Related to Acquisition by Rallybio - Wilson Sonsini
Rallybio and Candid Therapeutics To Merge - citybiz
Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? - Finviz
Candid, in a reverse merger with RallyBio, to go public - BioPharma Dive
Rallybio to acquire Candid Therapeutics in $505M deal - Investing.com
Watkins Advises on US$505 Million Financing in Connection With Rallybio-Candid Therapeutics Merger - Latham & Watkins LLP
Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline - MedCity News
Rallybio: Merger forms a TCE therapeutics leader with $500M+ capital to advance autoimmune disease pipeline - TradingView
Rallybio: Merger forms a top TCE therapeutics company with $700M cash, advancing a broad autoimmune pipeline - TradingView
Candid scores Nasdaq listing via reverse merger Rallybio - Fierce Biotech
Rallybio to merge with San Diego biotech in deal backed by $505M in financing - Hartford Business Journal
Rallybio to Merge with Candid Therapeutics in All-Stock Deal - TipRanks
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):